Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
RBI Uses $10 Billion Currency Swaps to Drain Excess Rupee Liquidity 
US Comfortable With Canada Trade Standoff as Import Bans Loom 
Soybean Futures Slip as Traders Await Trump-Xi Trade Signals 
Dollar Holds Near Two-Month High as Yen Approaches 160 
Fed Unveils Stablecoin Rules Under GENIUS Act 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
U.S. Dollar Hits Two-Month High as Oil, Treasury Yields Surge 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
UK PM Burnham to Unveil Economic Vision at Labour Conference 
Gold Holds Near $4,275 as Rising Treasury Yields Fuel Fed Rate Hike Bets 
Japanese Bank Stocks Surge as Bond Yields Fuel Rate Hike Bets 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Asian Currencies Mixed as Dollar Holds Near Two-Month High 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
Add as a preferred source on Google
Global pharmaceutical stocks dropped sharply Monday after former U.S. President Donald Trump pledged to cut prescription drug prices by up to 59% to align with prices in other wealthy countries. The announcement came via a Truth Social post, following a similar promise made just a day earlier, citing a potential 30% to 80% reduction “almost immediately.”
Major U.S. drugmakers including AbbVie, Amgen, Pfizer, Eli Lilly, and Merck fell between 2.2% and 3.7% in premarket trading. Biotech shares also declined amid fears of heightened regulatory scrutiny and pricing pressure. Jefferies analyst Michael Yee noted the sector could see increased volatility due to policy uncertainty.
Trump’s proposal aims to address the high cost of medications in the U.S., which often pays nearly triple the price compared to other developed nations. However, details on how the proposed cuts will be implemented remain unclear. Leerink Partners analyst David Risinger emphasized the need for clarity on the timeline and affected government programs.
European pharmaceutical stocks also took a hit, with a healthcare index dropping 2.9%. AstraZeneca, GSK, and Roche declined between 3.3% and 6.8%. Analysts warn the move could influence EU-U.S. trade negotiations, potentially substituting tariffs with pharmaceutical price caps.
India’s Biocon and Lupin slid as the U.S. remains their largest export market. In Australia, CSL Ltd and Mayne Pharma fell as healthcare stocks dropped to a multi-week low. Japan’s pharma sector plummeted 6.5%, with Daiichi Sankyo losing over 8%, marking it the worst-performing sector on the Tokyo Exchange. In Hong Kong, Alphamab Oncology tumbled 14.4%.
The global sell-off comes as the U.S. and China agree to ease mutual tariffs, signaling potential shifts in trade dynamics and global market sentiment.
